patent on semaglutide Off-patent in 2026: the next revolution in anti-obesity medications A Snapshot of the Semaglutide

Thymosin ?4: a multi-functional regenerative peptide

Intern Med 1994;33(2):82-86 7

2-9 They do this by: Building confidence and self-efficacy by empowering patients to actively engage with their treatment journey Educating patients to address the widespread misconception that obesity is not a disease, with 40% of patients unaware of this and 80% feeling solely responsible for their condition Implementing a whole-health approach to redefine treatment success, focus on overall health outcomes, not just weight loss Setting realistic expectations which prepares patients for the possibility of losing less weight than expected while still achieving significant health benefits Supporting medication adherence by providing tools for reminders, routines, titration guidance, and addressing injection anxiety Driving medication persistence as a result of setting realistic expectations and frame treatment around long-term health gains rather than short-term weight loss Mitigating side effects through equipping patients to self-manage common side effects through proactive tracking and helping them connect the dots Want to learn even more about how digital solutions can unlock the full potential of GLP-1 therapies

Researchers dont know exactly why some people dont respond

Discussing medical history and health status with healthcare providers is crucial to determine the suitability of this therapy

Speak to your healthcare provider if: Weight concerns are significantly affecting your mood or self-esteem You are considering stopping fluoxetine due to weight changes You notice signs of disordered eating patterns Weight issues are interfering with your recovery from depression, anxiety, or bulimia Your GP can help balance the benefits of fluoxetine for your mental health against any weight-related concerns, potentially adjusting treatment or providing additional support